OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
October 02, 2022
ROSS Ribbon Blenders are a customizable solution designed to minimize risk and maximize productivity.
The new inorganic pyrophosphate from Canvax is intended for use in RNA IVT reactions.
L.B. Bohle’s QbCon 1 is intended to meet all quality requirements for long granulation processing time.
Codex DNA’s BioXp 9600 system is designed for the automated synthesis of synthetic biology workflows.
The 1VQ papers advocate for the idea that certain post-approval changes should be streamlined and expedited.
September 30, 2022
Novo Nordisk will pay up to $700 million for the exclusive rights to develop and commercialize candidates from Ventus Therapeutics NLRP3 inhibitor portfolio.
FDA has approved Relyrio as a once-to-twice daily treatment for patients with ALS.
Citius and the University of Pittsburgh will investigate I/ONTAK in combination with pembrolizumab for treatment of recurrent or metastatic solid tumors.
Forge Biologics will offer three grades of plasmid manufacturing services at its Columbus, Ohio, location.
PerkinElmer has unveiled a cell analysis solution to streamline cell and gene therapy research and manufacturing.